184 related articles for article (PubMed ID: 37064291)
1.
Zhao L; Gong J; Qi Q; Liu C; Su H; Xing Y; Zhao J
Int J Nanomedicine; 2023; 18():1915-1925. PubMed ID: 37064291
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of an Anti-HER2 Nanobody Labeled with
Pruszynski M; D'Huyvetter M; Bruchertseifer F; Morgenstern A; Lahoutte T
Mol Pharm; 2018 Apr; 15(4):1457-1466. PubMed ID: 29502411
[TBL] [Abstract][Full Text] [Related]
3. Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling.
Pruszynski M; Koumarianou E; Vaidyanathan G; Revets H; Devoogdt N; Lahoutte T; Lyerly HK; Zalutsky MR
J Nucl Med; 2014 Apr; 55(4):650-6. PubMed ID: 24578241
[TBL] [Abstract][Full Text] [Related]
4. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
[No Abstract] [Full Text] [Related]
5. Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session.
Deken MM; Kijanka MM; Beltrán Hernández I; Slooter MD; de Bruijn HS; van Diest PJ; van Bergen En Henegouwen PMP; Lowik CWGM; Robinson DJ; Vahrmeijer AL; Oliveira S
J Control Release; 2020 Jul; 323():269-281. PubMed ID: 32330574
[TBL] [Abstract][Full Text] [Related]
6. Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody.
Pruszynski M; Koumarianou E; Vaidyanathan G; Revets H; Devoogdt N; Lahoutte T; Zalutsky MR
Nucl Med Biol; 2013 Jan; 40(1):52-9. PubMed ID: 23159171
[TBL] [Abstract][Full Text] [Related]
7. Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.
Keyaerts M; Xavier C; Heemskerk J; Devoogdt N; Everaert H; Ackaert C; Vanhoeij M; Duhoux FP; Gevaert T; Simon P; Schallier D; Fontaine C; Vaneycken I; Vanhove C; De Greve J; Lamote J; Caveliers V; Lahoutte T
J Nucl Med; 2016 Jan; 57(1):27-33. PubMed ID: 26449837
[TBL] [Abstract][Full Text] [Related]
8. (18)F-nanobody for PET imaging of HER2 overexpressing tumors.
Xavier C; Blykers A; Vaneycken I; D'Huyvetter M; Heemskerk J; Lahoutte T; Devoogdt N; Caveliers V
Nucl Med Biol; 2016 Apr; 43(4):247-52. PubMed ID: 27067045
[TBL] [Abstract][Full Text] [Related]
9. Preparation and
Okarvi SM; Aljammaz I
Anticancer Res; 2018 May; 38(5):2823-2830. PubMed ID: 29715105
[TBL] [Abstract][Full Text] [Related]
10. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM
J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.
Xavier C; Vaneycken I; D'huyvetter M; Heemskerk J; Keyaerts M; Vincke C; Devoogdt N; Muyldermans S; Lahoutte T; Caveliers V
J Nucl Med; 2013 May; 54(5):776-84. PubMed ID: 23487015
[TBL] [Abstract][Full Text] [Related]
12. Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation.
Choi J; Vaidyanathan G; Koumarianou E; Kang CM; Zalutsky MR
Nucl Med Biol; 2018 Jan; 56():10-20. PubMed ID: 29031230
[TBL] [Abstract][Full Text] [Related]
13. Imaging of HER2-Positive Tumors in NOD/SCID Mice with Pertuzumab Fab-Hexahistidine Peptide Immunoconjugates Labeled with [
Facca VJ; Al-Saden N; Ku A; Reilly RM
Mol Imaging Biol; 2021 Aug; 23(4):495-504. PubMed ID: 33479914
[TBL] [Abstract][Full Text] [Related]
14. Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.
D'Huyvetter M; Vincke C; Xavier C; Aerts A; Impens N; Baatout S; De Raeve H; Muyldermans S; Caveliers V; Devoogdt N; Lahoutte T
Theranostics; 2014; 4(7):708-20. PubMed ID: 24883121
[TBL] [Abstract][Full Text] [Related]
15.
Kwon LY; Scollard DA; Reilly RM
Mol Pharm; 2017 Feb; 14(2):492-501. PubMed ID: 28049295
[TBL] [Abstract][Full Text] [Related]
16. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
17. Radioiodinated Small-Molecule Tyrosine Kinase Inhibitor for HER2-Selective SPECT Imaging.
Tang L; Peng C; Tang B; Li Z; Wang X; Li J; Gao F; Huang L; Xu D; Zhang P; Zhuang R; Su X; Chen X; Zhang X
J Nucl Med; 2018 Sep; 59(9):1386-1391. PubMed ID: 29653973
[TBL] [Abstract][Full Text] [Related]
18.
D'Huyvetter M; De Vos J; Xavier C; Pruszynski M; Sterckx YGJ; Massa S; Raes G; Caveliers V; Zalutsky MR; Lahoutte T; Devoogdt N
Clin Cancer Res; 2017 Nov; 23(21):6616-6628. PubMed ID: 28751451
[No Abstract] [Full Text] [Related]
19. Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with
Cai Z; Yook S; Lu Y; Bergstrom D; Winnik MA; Pignol JP; Reilly RM
Pharm Res; 2017 Mar; 34(3):579-590. PubMed ID: 27987070
[TBL] [Abstract][Full Text] [Related]
20. Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation.
Zhou Z; Chitneni SK; Devoogdt N; Zalutsky MR; Vaidyanathan G
Bioorg Med Chem; 2018 May; 26(8):1939-1949. PubMed ID: 29534937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
